Bank of Nova Scotia’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $874K | Sell |
2,679
-1,827
| -41% | -$596K | ﹤0.01% | 773 |
|
|
2025
Q1 | $1.22M | Sell |
4,506
-6
| -0.1% | -$1.62K | ﹤0.01% | 701 |
|
|
2024
Q4 | $1.06M | Sell |
4,512
-1,971
| -30% | -$464K | ﹤0.01% | 765 |
|
|
2024
Q3 | $1.78M | Sell |
6,483
-151
| -2% | -$41.5K | ﹤0.01% | 671 |
|
|
2024
Q2 | $1.61M | Sell |
6,634
-6,729
| -50% | -$1.64M | ﹤0.01% | 688 |
|
|
2024
Q1 | $2M | Buy |
13,363
+7,338
| +122% | +$1.1M | ﹤0.01% | 654 |
|
|
2023
Q4 | $1.15M | Buy |
6,025
+3,077
| +104% | +$589K | ﹤0.01% | 751 |
|
|
2023
Q3 | $522K | Buy |
2,948
+457
| +18% | +$80.9K | ﹤0.01% | 790 |
|
|
2023
Q2 | $473K | Sell |
2,491
-760
| -23% | -$144K | ﹤0.01% | 829 |
|
|
2023
Q1 | $651K | Sell |
3,251
-1,160
| -26% | -$232K | ﹤0.01% | 793 |
|
|
2022
Q4 | $1.05M | Buy |
4,411
+1,004
| +29% | +$239K | ﹤0.01% | 801 |
|
|
2022
Q3 | $682K | Buy |
3,407
+813
| +31% | +$163K | ﹤0.01% | 897 |
|
|
2022
Q2 | $378K | Sell |
2,594
-4,569
| -64% | -$666K | ﹤0.01% | 1043 |
|
|
2022
Q1 | $1.17M | Buy |
7,163
+5,699
| +389% | +$931K | ﹤0.01% | 887 |
|
|
2021
Q4 | $249K | Buy |
+1,464
| New | +$249K | ﹤0.01% | 1125 |
|
|
2021
Q2 | – | Sell |
-3,110
| Closed | -$439K | – | 1030 |
|
|
2021
Q1 | $439K | Sell |
3,110
-1,291
| -29% | -$182K | ﹤0.01% | 947 |
|
|
2020
Q4 | $572K | Buy |
4,401
+146
| +3% | +$19K | ﹤0.01% | 840 |
|
|
2020
Q3 | $620K | Buy |
4,255
+515
| +14% | +$75K | ﹤0.01% | 784 |
|
|
2020
Q2 | $554K | Buy |
+3,740
| New | +$554K | ﹤0.01% | 722 |
|
|
2019
Q3 | – | Sell |
-43,790
| Closed | -$3.18M | – | 890 |
|
|
2019
Q2 | $3.18M | Buy |
43,790
+9,790
| +29% | +$710K | 0.01% | 510 |
|
|
2019
Q1 | $3.18M | Sell |
34,000
-140,000
| -80% | -$13.1M | 0.01% | 529 |
|
|
2018
Q4 | $12.7M | Buy |
+174,000
| New | +$12.7M | 0.06% | 236 |
|